Tasmar (Tolcapone) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Tasmar

Parkinson's Disease »

What is Parkinson's disease?

Parkinson's disease is the second most common neurodegenerative disorder and the most common movement disorder. It is characterized by progressive loss of muscle control, which leads to trembling of the limbs and head while at rest, stiffness, slowness, and impaired balance. As symptoms worsen, it may become difficult to walk, talk, and complete simple tasks.

The progression of Parkinson's disease and the degree of impairment vary from individual to individual. Many people with Parkinson's disease live long productive lives, whereas others become disabled much more quickly. Premature death is usually due to complications such as falling-related injuries or pneumonia.

In the United States, about 1 million people are affected by Parkinson's disease and worldwide about 5 million. Most individuals who develop Parkinson's disease are 60 years of age or older. Parkinson's disease occurs in approximately 1% of i...

Read the Parkinson's Disease article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Tasmar User Reviews >>

Tasmar

Parkinson's Disease Slideshow Pictures

Dementia Slideshow Pictures

Take the Parkinson's Quiz

font size

OVERDOSE

The highest dose of tolcapone administered to humans was 800 mg tid, with and without levodopa/carbidopa coadministration. This was in a 1-week study in elderly, healthy volunteers. The peak plasma concentrations of tolcapone at this dose were on average 30 μg/mL (compared to 3 μg/mL and 6 μg/mL with 100 mg and 200 mg tolcapone, respectively). Nausea, vomiting and dizziness were observed, particularly in combination with levodopa/carbidopa.

THE THRESHOLD FOR THE LETHAL PLASMA CONCENTRATION FOR TOLCAPONE BASED ON ANIMAL DATA IS > 100 μG/ML. RESPIRATORY DIFFICULTIES WERE OBSERVED IN RATS AT HIGH ORAL (GAVAGE) AND INTRAVENOUS DOSES AND IN DOGS WITH RAPIDLY INJECTED INTRAVENOUS DOSES.

Management of Overdose

Hospitalization is advised. General supportive care is indicated. Based on the physicochemical properties of the compound, hemodialysis is unlikely to be of benefit.

CONTRAINDICATIONS

TASMAR (tolcapone) tablets are contraindicated in patients with liver disease, in patients who were withdrawn from TASMAR (tolcapone) because of evidence of TASMAR (tolcapone) -induced hepatocellular injury or who have demonstrated hypersensitivity to the drug or its ingredients.

TASMAR (tolcapone) is also contraindicated in patients with a history of non-traumatic rhabdomyolysis or hyperpyrexia and confusion possibly related to medication (see PRECAUTIONS: Events Reported With Dopaminergic Therapy).

Last reviewed on RxList: 3/12/2009
This monograph has been modified to include the generic and brand name in many instances.